FY25 consensus $6.51. Raises FY25 revenue view to $818M-$843M from $768M-$793M, consensus $791.48M. Raises FY25 adjusted EBITDA view to $213M-$223M from $195M-$205M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- Is ANIP a Buy, Before Earnings?
- Positive Outlook on ANI Pharmaceuticals Despite Legal Setback: Buy Rating Reaffirmed
- ANI Pharmaceuticals to Challenge Court Verdict
- CG Oncology announces Delaware Superior Court ruling in its favor
- Optimistic Growth Potential for ANI Pharmaceuticals Despite Challenges in DME Treatment